TY - JOUR T1 - Relationship between Clinicopathological Characteristics &amp; PET/CT Uptakes in Esophageal Squamous Cell Carcinoma Patients: <sup>18</sup>F-Alfatide versus [<sup>18</sup>F]DG JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 245 LP - 245 VL - 59 IS - supplement 1 AU - Yu-Chun Wei AU - Shuanghu Yuan AU - Li Li AU - Jinming Yu Y1 - 2018/05/01 UR - http://jnm.snmjournals.org/content/59/supplement_1/245.abstract N2 - 245Purpose: To assess a novel radiotracer 18F-Aluminum fluoride-1,4,7-triazacyclononane-triacetic acid-pegylated dimeric RGD (18F-ALF-NOTA-PRGD2, denoted as18F-Alfatide) positron emission tomography (PET)/computed tomography (CT) &amp; explore the relationship between clinicopathological characteristics &amp; maximum standard uptake in primary (SUVP) &amp; metastatic lymph nodes (SUVLN) in patients with esophageal squamous cell carcinoma (ESCC), verified by pathologic examination &amp; compared with those using 2-deoxy-2-[18F]fluoro-D-glucose ([18F]DG). Methods: Sixty-one patients with newly diagnosed esophageal cancer underwent 18F-Alfatide PET/CT (n=29) &amp; [18F]DG PET/CT (n=32) scans before surgery within 3 days. SUVs, pathological tumor-node-metastasis (pTNM) stage of primary tumor &amp; metastatic lymph nodes (LNs) were measured, &amp; diagnoses were pathologically confirmed. Results: Forty-six patients underwent curative surgery &amp; PET/CT scans, including 18F-Alfatide (n=21) &amp; [18F]DG (n=25). No significantly different SUVP of 18F-Alfatide PET/CT was observed among the cohorts based on gender, pathological stage, T stage, status of LN &amp; differentiation, respectively, as well as [18F]DG PET/CT, P&gt;0.05. A significant difference was observed in SUVLN between the pathological stages &amp; status of LN both in 18F-Alfatide PET/CT (P were 0.03 &amp; 0.003) &amp; [18F]DG PET/CT (P were 0.001 &amp; &lt;0.001), but not in gender (P=0.128, 0.129), T stage (P=0.791, 0.727), or tumor differentiation (P=0.049, 0.053). Significant positive correlations between the SUVLN &amp; pathological stage (r=0.52, P=0.016), status of LN (r=0.73, P&lt;0.001), or differentiation (r=0.509, P&lt;0.019) of 18F-Alfatide PET/CT were observed, &amp; those of [18F]DG PET/CT were r=0.503, P=0.01; r=0.649, P&lt;0.001; r=0.459, P=0.021, respectively. Relationships of SUVP between SUVLN, length, age, gender, pathological stage, T stage, status of LN, or differentiation, &amp; of SUVLN between length, age, gender, or T stage had no statistical differences in either 18F-Alfatide PET/CT or [18F]DG PET/CT, P&gt;0.05. Conclusions: These findings suggest that SUVLN was influenced by pathological stage &amp; LN status &amp; differentiation. SUVLN may therefore serve as a new parameter for patient stratification with ESCC. 18F-Alfatide PET can provide complementary molecular information about ESCC metastasis. ER -